Passage Bio, Inc. develops clinical-stage genetic medicines for neurodegenerative diseases, with news centered on PBFT02 and the upliFT-D study in frontotemporal dementia. Company updates commonly address safety and biomarker data, progranulin and neurofilament light-chain measures, patient groups involving FTD-GRN and FTD-C9orf72, and FDA interactions tied to potential registrational development.
Recurring announcements also cover periodic financial results, corporate presentations, investor conference participation, manufacturing comparability work, and strategic or operating updates that affect the company's development plans and expense profile.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.